Barclays
TXG icon

Barclays’s 10x Genomics TXG Stock Holding History

Barclays’s Portfolio TXG Stock Details TXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$9.04M Buy
99,997
+65,499
+190% +$3.83M ﹤0.01% 1699
2026
Q2 		$1.32M Buy
34,498
+5,400
+19% +$142K ﹤0.01% 2624
2026
Q1 		$618K Sell
29,098
-288,884
-91% -$5.78M ﹤0.01% 3061
2025
Q4 		$5.19M Sell
317,982
-187,409
-37% -$2.83M ﹤0.01% 2194
2025
Q3 		$5.91M Sell
505,391
-471,597
-48% -$6.15M ﹤0.01% 2064
2025
Q2 		$11.3M Buy
976,988
+191,158
+24% +$1.74M ﹤0.01% 1489
2025
Q1 		$6.86M Sell
785,830
-5,127
-0.6% -$64.6K ﹤0.01% 1671
2024
Q4 		$11.4M Buy
790,957
+188,421
+31% +$2.97M ﹤0.01% 1479
2024
Q3 		$13.6M Buy
602,536
+80,579
+15% +$1.67M ﹤0.01% 1269
2024
Q2 		$10.2M Buy
521,957
+464,221
+804% +$12.2M ﹤0.01% 1187
2024
Q1 		$2.17M Sell
57,736
-208,562
-78% -$9.16M ﹤0.01% 2491
2023
Q4 		$14.9M Buy
266,298
+244,099
+1,100% +$10.6M 0.01% 1227
2023
Q3 		$916K Buy
22,199
+584
+3% +$30.4K ﹤0.01% 2389
2023
Q2 		$1.21M Buy
21,615
+9,970
+86% +$540K ﹤0.01% 2187
2023
Q1 		$650K Sell
11,645
-160,027
-93% -$7.47M ﹤0.01% 3074
2022
Q4 		$6.26M Buy
171,672
+145,505
+556% +$4.76M ﹤0.01% 1466
2022
Q3 		$745K Buy
26,167
+3,815
+17% +$145K ﹤0.01% 2436
2022
Q2 		$1.01M Sell
22,352
-18,061
-45% -$937K ﹤0.01% 2336
2022
Q1 		$3.07M Buy
+40,413
New +$3.54M ﹤0.01% 1539

Other funds holding TXG

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
ARK Investment Management
ARK Investment Management St. Petersburg, Florida $17.4B AUM 41.01% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Quantinno Capital Management
Quantinno Capital Management New York $106B AUM 29.93% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Barclays's TXG Position: Q3 2026 in Review

Barclays increased its 10x Genomics (TXG) stake by 190% in Q3 2026, buying an estimated $3.83M and bringing the position to 99,997 shares worth $9.04M. The position accounts for ﹤0.01% of the portfolio, ranked #1699.

Barclays first reported a position in TXG in Q1 2022 and has held it in 19 quarters since. The position peaked at $14.9M in Q4 2023. 377 funds tracked by Wall St. Rank hold TXG as of Q3 2026.

  • Barclays held 99,997 shares of 10x Genomics worth $9.04M as of Q3 2026.
  • Barclays bought 65,499 10x Genomics shares in Q3 2026, an estimated $3.83M.
  • 10x Genomics made up ﹤0.01% of Barclays's portfolio in Q3 2026, its #1699 holding.
  • Barclays first reported a position in 10x Genomics in Q1 2022 and has held it in 19 quarters since.
  • Barclays's 10x Genomics position peaked at $14.9M in Q4 2023.
  • 377 funds tracked by Wall St. Rank held 10x Genomics as of Q3 2026.

Based on Barclays's 13F filing for Q3 2026, filed 6 Nov 2026.